MiR-374a suppresses lung adenocarcinoma cell proliferation and invasion by targeting TGFA gene expression.

Wu H, Liu Y, Shu XO, Cai Q
Carcinogenesis. 2016 37 (6): 567-75

PMID: 27207663 · PMCID: PMC4876989 · DOI:10.1093/carcin/bgw038

Aberrant expression of miR-374a has been reported in several types of human cancers, including lung cancer. However, the functional significance and molecular mechanisms underlying the role of miR-374a in lung cancer remain largely unknown. We found that the expression of miR-374a was significantly downregulated in lung adenocarcinoma tissues compared to adjacent normal lung tissues in samples included in The Cancer Genome Atlas. Functional studies revealed that overexpression of miR-374a led to inhibition of lung adenocarcinoma cell proliferation, migration and invasion and that miR-374a negatively regulated transforming growth factor-alpha (TGFA) gene expression by directly targeting the 3'-UTR of TGFA mRNA. Treating lung adenocarcinoma cells with TGF-α neutralizing antibody resulted in suppression of cell proliferation and invasion, which mimicked the action of miR-374a. Additionally, TGFA gene expression was significantly higher in tumor tissues compared to adjacent normal tissue and high TGFA gene expression strongly correlated with poor survival in patients with lung adenocarcinoma. Taken together, our studies suggest that miR-374a suppresses lung adenocarcinoma cell proliferation and invasion via targeting TGFA gene expression. Our findings may provide novel treatment strategies for lung adenocarcinoma patients.

© The Author 2016. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.

MeSH Terms (13)

3' Untranslated Regions Adenocarcinoma Adenocarcinoma of Lung Antibodies, Neutralizing Cell Line, Tumor Cell Movement Cell Proliferation Gene Expression Regulation, Neoplastic Humans Lung Lung Neoplasms MicroRNAs Transforming Growth Factor alpha

Connections (1)

This publication is referenced by other Labnodes entities: